GLP1 agonists associated with a reduced risk of developing cirrhosis and liver cancer in people with T2DM and chronic liver disease
Glucagon-like peptide-1 receptor (GLP1) agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people...
